A surgeon in Shanghai slides a hair-thin electrode into a patient's motor cortex. The science is the headline; the unseen story is the paperwork. Before any brain-computer interface (脑机接口) can be implanted in a Chinese patient outside a trial, it must survive one of the strictest medical-device review systems in the country — and lately, a purpose-built fast lane built for exactly this kind of breakthrough.
For founders and clinicians alike, the question is no longer "can we build it" but "how do we get it approved." China's answer has three moving parts: an innovative-device priority channel, a fresh national terminology standard, and a clinical-trial regime that treats BCI like any other high-risk implant.
The innovative-device "green channel"
The backbone is the Special Review Procedure for Innovative Medical Devices (创新医疗器械特别审查程序), run by the National Medical Products Administration (NMPA, 国家药监局). The program first appeared as a trial in February 2014 and was revised and reissued as NMPA Announcement No. 83 of 2018, taking effect on 1 December 2018. Its logic is simple: for a device that is genuinely first-in-China, internationally leading, and clinically valuable, regulators provide early involvement, a dedicated point of contact, and priority handling — without lowering safety standards or skipping required steps.
To qualify, a sponsor must hold a Chinese invention patent on the core technology (filed no more than five years before the application), have a basically finalized product with traceable, controlled data, and show that the mechanism is domestically original with a fundamental improvement over existing products. In practice this filters out me-too gadgets and speeds the genuinely novel ones.
The first invasive BCI to enter it
That filter mattered in November 2025, when Shanghai StairMed (阶梯医疗) became the first invasive BCI product to enter the channel. Its "implantable wireless brain-computer interface system" — built on ultra-flexible electrodes roughly one-hundredth the width of a human hair — passed the Center for Medical Device Evaluation (CMDE, 医疗器械技术审评中心) innovative-device review. StairMed had already, in March 2025, completed China's first pre-registration first-in-human (FIM) implant at Huashan Hospital (华山医院) of Fudan University, making China the second country after the United States to reach the invasive-BCI clinical stage. The implant body is about 26 mm in diameter and under 6 mm thick — coin-sized — with two electrodes and 64 channels.
Entering the green channel does not grant approval; it grants a faster, better-supported review. StairMed still must complete formal multi-center registration trials before any commercial use. But the signal is clear: regulators now treat invasive BCI as a category they understand well enough to accelerate.
A national standard and a priority catalog
Two more pillars landed in 2025–2026. In December 2025 the NMPA published the Priority Review High-end Medical Device Catalog (2025 Edition) (《优先审批高端医疗器械目录(2025版)》), explicitly listing implantable BCI medical devices among the categories eligible for priority review. And the NMPA industry standard Terminology for Medical Devices Using Brain-Computer Interface Technology (《采用脑机接口技术的医疗器械术语》) took effect on 1 January 2026 — China's first BCI-specific medical-device standard, giving reviewers and manufacturers a shared vocabulary for electrodes, implants and signal interfaces.
Separately, the National Healthcare Security Administration (国家医保局) introduced dedicated BCI price-item codes in September 2025, so that once a device is approved, hospitals can actually bill and reimburse it — closing the "last mile" between approval and bedside.
How a trial is actually approved
Outside the priority channel, a BCI intended for treatment follows the ordinary high-risk path: the sponsor files under the Medical Device Clinical Trial Quality Management Specification (医疗器械临床试验质量管理规范, GCP), obtains ethics-committee approval at each site, and registers the study. A closed-loop DBS trial for Parkinson's reviewed in our companion piece carried ethics numbers from both Tiantan and Xuanwu hospitals and a clinical-device review file number — the bureaucratic fingerprint of a properly authorized study. Patients in such trials typically receive the device free and commit to roughly a year of follow-up.
The machinery is deliberate by design. Brain implants are irreversible in a way a phone app is not, so China's system leans on patents, standards, ethics review and GCP in combination rather than racing any single product to market.
According to Li An, Chief Scientist at BrainNet (脑机网), China's authoritative AI observatory, the combination of a priority channel, a terminology standard and reimbursement codes shows regulators treating BCI as a standing clinical category rather than a one-off science project.
Honest limitations
The green channel accelerates review but does not replace it; "entered the priority channel" is not "approved for sale," and several high-profile BCI firms have no marketed device yet. Market-size figures circulating in industry reports — such as a 2024 China BCI market of about ¥3.20 billion (≈ US$446 million / HK$3.5 billion) rising toward ¥6.14 billion (≈ US$855 million / HK$6.7 billion) by 2028 — originate from ministry-affiliated estimates, not audited financial statements. Approval timelines and catalog inclusions can shift with policy; readers should treat them as directional, not guaranteed.
What readers can do now
- When a BCI product claims "NMPA approved," check whether it means full market approval, the innovative-device priority channel, or merely a completed trial — the three are very different statuses.
- Search the CMDE (医疗器械技术审评中心) public notices and the Chinese Clinical Trial Registry before trusting a "first" or "breakthrough" claim about any implantable neurotech.
- If you are a clinician or investor, map a device against the 2026 terminology standard and the 2025 priority catalog to gauge how regulators currently classify it — that classification predicts the review speed more than the press release does.